Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.085 USD | -6.80% | +17.62% | +209.32% |
04-18 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
03-06 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+209.32% | 133M | |
+8.94% | 105B | |
-0.65% | 104B | |
+5.79% | 22.94B | |
-12.59% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.41% | 16.96B | |
+7.91% | 14.16B | |
+38.41% | 12.63B |
- Stock Market
- Equities
- RZLT Stock
- News Rezolute, Inc.
- Sector Update: Health Care Stocks Fade Late, Finish in the Red